

20 November 2018

NSX Announcement

Status of Medicine Plus Agreement

Beroni Group Limited (NSX:BTG) (“Beroni” or “the Company”) wishes to advise that the Company and Medicine Plus Co., Ltd (“MP”) are currently in discussion to mutually extend the settlement date. Formal variation deed is being prepared to facilitate the extension and the Company will make a separate announcement to the market once both parties have executed the deed.

For further information please contact:

Mr Jacky Zhang
Executive Chairman

Tel: +86 1851 6931 911

E: jacky.zhang@beronigroup.com

Mr Peter Wong

Executive Director and CFO

Tel: +61 423 727 580

E: peter.wong@beronigroup.com

About Beroni Group Limited (NSX:BTG)

Beroni Group is an international biotechnological company listed on the National Stock Exchange of Australia. It currently has four core businesses - cell therapies, developing new anti-cancer drugs, e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases.

Beroni Group’s overall strategic goal is to become a world’s leading enterprise in the biotechnology, life sciences and environmental science industries.